Many cancer therapies are limited not by their biology but by delivery. Solid tumours build up interstitial fluid pressure, and standard catheters can struggle to push therapy into the tumour rather than into surrounding healthy tissue.
On September 22, 2026, TriSalus Life Sciences (Nasdaq: TLSI) announced FDA 510(k) clearance for TriNav Advance, the newest device in its Pressure-Enabled Drug Delivery (PEDD) portfolio. It extends the company's SmartValve approach to small, distal hepatic vessels.
